Is the 'Kurus Injection' Safe? What Malaysians Need to Know About GLP-1 Safety

In Malaysia, GLP-1 weight loss medications are commonly referred to as 'suntikan kurus', literally 'slimming injection'. This colloquial term is widespread on social media and in informal health discussions. But many Malaysians have understandable questions: are these injections actually safe? What are the risks? Who should not take them? This article answers those questions clearly, based on clinical evidence.

What Is 'Suntikan Kurus'?

The term 'suntikan kurus' is used loosely in Malaysian conversations to describe injectable weight loss treatments. In most clinical contexts today, this refers to GLP-1 receptor agonists, medications containing semaglutide or liraglutide that are prescribed for medically appropriate weight management.

These are not 'slimming injections' in the aesthetic sense. GLP-1 receptor agonists are prescription medications originally developed for type 2 diabetes management and subsequently approved for chronic weight management by major regulatory bodies worldwide. They work by mimicking a natural gut hormone that regulates appetite and insulin secretion, a very different mechanism from aesthetic fat-dissolving injections or traditional weight loss supplements.

It is important to distinguish GLP-1 medications from unregulated alternatives sometimes marketed as 'suntikan kurus' in beauty salons or online, which may contain unknown compounds and carry serious safety risks. The GLP-1 medications prescribed through licensed clinics like Seimbang are regulated prescription drugs with well-established safety profiles.

What Does the Clinical Evidence Say About Safety?

GLP-1 medications are among the most rigorously studied weight loss treatments in history. The STEP clinical trial programme, which evaluated semaglutide, enrolled over 16,000 patients across multiple countries and monitored them for periods ranging from 68 weeks to 4 years. This scale of evidence is exceptional by any standard in obesity medicine.

Regulatory approval has been granted by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other major health authorities. These approvals were based on comprehensive review of safety and efficacy data. The medications continue to be monitored through post-market pharmacovigilance programmes.

The most commonly reported side effects in clinical trials were gastrointestinal: nausea, vomiting, diarrhoea, and constipation, which were generally mild to moderate, most pronounced during the dose escalation phase, and resolved over time. No evidence of serious cardiovascular harm was found in non-diabetic patients; the SELECT trial (17,604 patients) actually demonstrated significant cardiovascular risk reduction with semaglutide.

What Are the Real Risks?

The most common real risks of GLP-1 treatment are gastrointestinal. Nausea affects approximately 44% of patients during dose escalation, vomiting approximately 24%, and diarrhoea approximately 30%. These effects are manageable through gradual dose titration, dietary adjustments, and physician guidance. Rare but more serious risks include pancreatitis, which patients should be screened for and monitored against, and gallstone formation, which appears to be linked to rapid weight loss rather than the medication itself.

Thyroid C-cell tumours were observed in rodent studies at high doses; however, no causal link has been established in human patients across years of clinical trials and post-market surveillance. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) are excluded from GLP-1 treatment as a precaution. If you experience sudden or severe abdominal pain that does not resolve, or any unusual symptoms, you should contact your doctor immediately.

5 Factors That Make GLP-1 Treatment Safe

Who Should NOT Take GLP-1 Injections?

GLP-1 medications are contraindicated for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). They are also not appropriate for patients with a history of acute pancreatitis, those who are pregnant or breastfeeding, or patients with severe renal or hepatic impairment. A thorough medical history review is essential before any prescription is issued.

Patients with active or previous eating disorders, or those taking medications that interact significantly with GLP-1 drugs, should also discuss these conditions with their doctor before starting treatment. At Seimbang, every patient undergoes a comprehensive eligibility assessment to ensure GLP-1 treatment is both safe and appropriate for their individual health profile.

Is Suntikan Kurus Safe Through Seimbang?

When administered through a proper clinical pathway, with comprehensive pre-treatment screening, physician-issued prescriptions, supervised dose titration, and regular medical follow-up. GLP-1 treatment has an established and well-understood safety profile. The risks are real but manageable, particularly under physician supervision.

Seimbang's clinical process is designed specifically to ensure safe treatment for every patient. Our MMC-registered physicians review your full medical history, current medications, and health status before any prescription is issued. Dose titration is conducted according to clinical guidelines, and patients have direct access to their doctor throughout their treatment journey.

Frequently Asked Questions